NC Registry
The majority of NMCs cases are attributed to the fusion of the NUT gene to either BRD4 or BRD3, creating chimeric genes that encode BRD-NUT fusion proteins. In the remaining cases, NUT is fused to an unknown partner gene; these tumors are termed NUT-variant. Our NMC Registry team collects clinical data regarding response to various treatments, which may facilitate future therapeutic strategies.
There is a clinical trial combining a BET inhibitor, ZEN003694, with chemotherapy treatment (etoposide and cisplatin) for adult and pediatric patients (12-17 Years) with NUT Carcinoma. Additional information about this trial can be found at the following link:
https://clinicaltrials.gov/ct2/show/NCT05019716?term=NCT05019716&draw=2&rank=1
Click here to claim your Sponsored Listing.
Category
Telephone
Website
Address
New Research Building Rm 630G, 77 Avenue Louis Pasteur
Boston, MA
02115
